We will email you to start the conversation.
Albert Labs’ Daniel Sanders explains its partnership with the University of CESPU health sciences department in Portugal.
Toxicology is hugely important in pre-clinical drug stages, he says and through the partnership Albert Labs will be establishing good laboratory practices within CESPU’s facility and be able to monitor all aspects of toxicology during pre-clinical trials.
Dr Michael Raymont, chief executive of Albert Labs, spoke to Proactive about the toxicology research for KRN-101.
KRN-101 is a psilocybin-based drug, and is used as a treatment for cancer-related anxiety.
Dr Raymont said the company is getting ready to trial this in the Autumn, and investors should know it is making steady progress.
© 2022 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact firstname.lastname@example.org